- Home
- TRNI vs NUVB Comparison
TRNI vs NUVB Comparison
Compare TRNI & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRNI | NUVB |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TRNI | NUVB |
|---|---|---|
| Price | $25.32 | $6.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.38 |
| AVG Volume (30 Days) | 8.5K | ★ 5.9M |
| Earning Date | N/A | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 71.56 |
| EPS | ★ 0.85 | N/A |
| Revenue | N/A | ★ $62,902,000.00 |
| Revenue This Year | N/A | $203.82 |
| Revenue Next Year | N/A | $58.18 |
| P/E Ratio | $29.76 | ★ N/A |
| Revenue Growth | N/A | ★ 698.96 |
| 52 Week Low | $25.21 | $2.84 |
| 52 Week High | $25.38 | $9.75 |
Technical Indicators
Market Signals| Indicator | TRNI | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 53.40 | 58.62 |
| Support Level | $25.22 | $5.28 |
| Resistance Level | $25.36 | $8.95 |
| Average True Range (ATR) | 0.07 | 0.38 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 64.71 | 60.88 |
Price Performance
Historical ComparisonAbout NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.